Immunogenicity of therapeutic proteins

Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition

Volumn , Issue , 2013, Pages 133-141

  Schellekens, Huub ^a   Jiskoot, Wim ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; MEDICAL APPLICATIONS;

ANTIGEN-ANTIBODY COMPLEX; IDENTIFICATION CARDS; IMMUNE RESPONSE; IMMUNOGENICITY; REGULATORY SYSTEMS; SERUM THERAPY; SIDE EFFECT; THERAPEUTIC PROTEIN;

PROTEINS;

EID: 84907817745     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6486-0_6     Document Type: Chapter

References (17)

1. Arnold DF, Misbah SA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Engl J Med 19: 358
2. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM (1993) The influence of antigen organization on B-cell responsiveness. Science 262: 1448-1451
3. Casadevall N, Nataf J, Viron B et al (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475
4. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21: 897-903
5. Hermeling S, Jiskoot W, Crommelin DJA, Bornaes C, Schellekens H (2005) Development of a transgenic mouse model immune tolerant for human interferon β. Pharm Res 22: 847-851
6. Mire-Sluis AR, Barrett YC, Devanarayan V et al (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289: 1-16
7. Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51: 691-697
8. Ryff JC (1997) Clinical Investigation of the immunogenicity of interferon alpha 2a. J Interferon Cytokine Res 17: S29-S33
9. Sauerborn M, Brinks V, Jiskoot W, Schellekens H (2010) Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31(2): 53-59
10. Schellekens H (2002) Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1: 1-7
11. Stevanovic S (2002) Structural basis of immunogenicity. Transpl Immunolog 10: 133-136
12. Stevanovic S (2005) Antigen processing is predictable: from genes to T cell epitopes. Transpl Immunol 14: 171-174
13. Weigle WO (1971) Recent observations and concepts in immunological unresponsiveness and autoimmunity. Clin Exp Immunol 9: 437-447
14. Brinks V, Jiskoot W, Schellekens H (2011) Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 28(10): 2379-2385
15. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2007) Immunogenicity of therapeutic proteins. In: Gad SC (ed) Handbook of pharmaceutical biotechnology. Wiley, Hoboken, pp 911-931
16. Schellekens H (2010) The immunogenicity of therapeutic proteins. Discov Med 9: 560-564
17. Schellekens H, Crommelin D, Jiskoot W (2007) Immunogenicity of antibody therapeutics. In: Dübel S (ed) Handbook of therapeutic antibodies. Wiley-VCH, Weinheim, pp 267-276